( September 3, 2025, 11:53 AM EDT) -- TRENTON, N.J. — After its second amended complaint (SAC) against a pharmaceutical manufacturer — filed in connection with its purchase of large quantities of hydroxychloroquine and chloroquine phosphate during the COVID-19 pandemic — was stricken for failure to comply with local rules, a pharmaceutical supplier refiled its SAC alleging that the manufacturer breached a sales contract by not refunding the supplier for unsold products or providing price protection....